VERNON, BC – September 20, 2018 – PRESS RELEASE – True Leaf Medicine International Ltd., a plant-forward wellness brand for people and their pets, has announced the appointment of Kerry Biggs, CPA, MBA, as chief financial officer.
Biggs has more than 20 years of finance and business experience, most recently with lululemon athletica, where he was vice president and treasurer, looking after capital markets, liquidity, treasury, insurance and risk activities for the NASDAQ-listed company. Previously, he served as vice president of finance at global container terminals, where he was responsible for capital markets, risk management, accounting, tax planning and corporate M&A activities. He also worked in senior finance roles for Finning International and Enbridge, both large, publicly traded companies.
“Mr. Biggs has held leadership roles for several prominent Canadian public companies with premium global brands,” said Darcy Bomford, founder and chief executive officer of True Leaf. “He has a strong understanding of a business’s key performance drivers and a solid history of adding value by driving operational efficiencies. This experience will be invaluable to True Leaf as we continue to grow exponentially.”
“Joining True Leaf is a unique opportunity to work for a strong company with a leading position in the high-growth pet and cannabis markets, and with an established global distribution of its legal products,” said Biggs. “I am most looking forward to working with the team to tell True Leaf’s growth story to the market.”
Biggs holds an MBA from the Richard Ivey School of Business (University of Western Ontario), a Chartered Professional Accountant designation, and a Bachelor of Arts, Political Science degree from the University of Victoria.
The company also announced it has granted stock options to officers and consultants to purchase up to a total 1,050,000 common shares, exercisable at a price of 56 cents per share, which was the closing price of the company's shares on Sept. 10, 2018, being the date of grant. The majority of the stock options are exercisable for five years until Sept. 10, 2023.
